Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

A biopharmaceutical company focused exclusively on metabolic dysfunction-associated steatohepatitis (MASH), having secured ...

Nick Madrigal's first foray into the shortstop position did not go as planned. The Mets infielder suffered a dislocated left shoulder on a slow roller on the infield grass during the first inning of ...

The latest announcement is out from Madrigal Pharmaceuticals ( (MDGL) ).

Mets infielder Nick Madrigal has been diagnosed with a fracture in his left shoulder after undergoing an MRI, manager Carlos Mendoza announced to the team’s beat this morning (via Anthony DiComo of ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Madrigal Pharmaceuticals earned an important regulatory approval this year. However, the biotech faces risks, including the need for a post-marketing study. While the new medicine has good potential, ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. According to ...

Madrigal Pharmaceuticals, Inc. has secured a $500 million senior secured credit facility from Blue Owl Capital to advance its pipeline focused on treating metabolic dysfunction-associated ...

Nick Madrigal charged in from third base and fired across his body Tuesday morning as a few raindrops fell on a cool day at the Chicago Cubs spring training complex. Madrigal spent half of his infield ...